Autres langues Compugen Ltd.

Actions

CGEN

IL0010852080

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 17/05/2024			Varia. 5j.	Varia. 1 janv.
2,11 ^USD	-1,40 %		+4,98 %	+6,57 %

15/05	Compugen nomme David Silberman directeur financier	MT
08/03	COMPUGEN LTD. : Truist Securities optimiste sur le dossier	ZM

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Compugen : Publishes Paper in Cancer Immunology Research on Unique Biology of PVRIG and its Therapeutic Potential	16/05
Compugen Names David Silberman CFO	15/05
Compugen Appoints David Silberman as Chief Financial Officer	15/05
Compugen Ltd. Announces CFO Changes, Effective August 15, 2024	15/05
Compugen to Release First Quarter 2024 Results on Monday, May 20, 2024	06/05
Compugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024	26/04
Compugen : To Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024	25/04
Compugen to Participate in Two Upcoming Investor Conferences	03/04
Compugen : Selected for two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy	11/03
Compugen Selected for two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy	11/03
Compugen to Present Data Reflecting its Diversified Immuno-Oncology Pipeline at AACR 2024	07/03
Compugen : To Present Data Reflecting its Diversified Immuno-Oncology Pipeline at AACR 2024	06/03
Compugen: Q4 Earnings Snapshot	05/03
Earnings Flash (CGEN) COMPUGEN Reports Q4 Revenue $33.5M	05/03
Earnings Flash (CGEN) COMPUGEN Posts Q4 EPS $0.11	05/03
Compugen : Form 6-K- Fourth quarter and full year 2023 results	05/03
Earnings Flash (CW9) COMPUGEN Posts Q4 EPS $0.11	05/03
Compugen Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	05/03
Compugen Reports Fourth Quarter and Full Year 2023 Results	05/03
Compugen to Present at the Leerink Partners Global Biopharma Conference 2024	26/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Compugen Ltd.

Actions

CGEN

IL0010852080

Autres langues

Filtres